FRI0444 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS FOLLOWING INADEQUATE RESPONSE TO SYNTHETIC OR BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN REAL-LIFE SETTINGS

Background The data regarding the efficacy and safety of Secukinumab (SEC) in patients with psoriatic arthritis (PsA) in daily clinical practice are scarce. Objectives To assess the safety and efficacy of SEC in patients with PsA in real life settings. Methods All PsA patients treated with SEC in the Rheumatology Units of 2 referral University Hospitals were prospectively included (from 3/2016-12/2018). Patients’ characteristics, treatments and indices of disease activity (DAPSA, DAS28-CRP, BASDAI) and function (HAQ, BASFI) as well as the extent of skin disease (BSA) were recorded at baseline and during therapy. Results 79 patients treated with SEC were included; 75% were females (n=59) with a mean age of 54±13.4 years, a median disease duration of 7.8 years and a median SEC treatment duration of 10 months (IQR 13). At baseline, 42% had axial involvement, 25% enthesitis and 13% dactylitis. The majority of patients had previously failed anti-TNFs (91%, n=72; n=1: 32%, n=2: 43% or n≥3: 25%), anti-IL12/23 (37%), both biologic agents (34%) or apremilast (5%). SEC was administered in combination with csDMARDs in 55% and corticosteroids in 40% of patients, respectively. At the end of the follow-up period (median: 15 months), patients’ disease activity (median DAPSA: 29 → 18.5, p Conclusion In a large, real life, cohort of patients with PsA, resistant to different biologics (anti-TNFs and/or anti-IL12/23), SEC displayed a high retention rate (63% after a median follow-up of 15 months) without significant side effects. These data emphasize the role of SEC as a viable therapeutic option even in patients with difficult to treat, multi-resistant PsA in daily clinical practice. Acknowledgement This work was supported by research grants from the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece Disclosure of Interests None declared